Early trial data suggest RNA therapies SRP-1001 and SRP-1003 reach muscle and show biomarker activity in muscular dystrophy.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...
Myotonic dystrophy is a condition that causes thinned muscles, decreased muscle tone, and muscle weakness. Over time, a person may lose their strength and have issues relaxing their muscles. The ...
A person may inherit the genetic changes responsible for muscular dystrophy. These genetic changes can also occur due to spontaneous genetic mutations. In either case, the disease is not preventable.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results